SWOG S1815 показывает необходимость в оценке триплетной химиотерапии, специфичной для подгруппа при раке желчных путей
Рачна Шрофф, MD, MS, FASCO Signals of efficacy observed with the addition of nab-paclitaxel (Abraxane) to gemcitabine and cisplatin (GAP) in select subgroups of patients with newly diagnosed advanced biliary tract cancers reinforce the biological heterogeneity of these malignancies and highlight the need for further prospective studies to clarify the triplet’s potential role according to … Read more